In 2023, the world's first CRISPR-based gene therapy — Casgevy — was approved in the UK and US for sickle cell disease. That approval was a watershed moment. But it was also just the beginning. In 2026, the pipeline of approved and late-stage gene therapies has grown dramatically, and the types of conditions being treated have expanded far beyond rare genetic diseases.
Here's a clear-headed look at where gene therapy stands today — what it can do, what it can't, and what's coming next.
Breakthrough 1: Sickle Cell Disease — The First Functional Cure
Casgevy (exa-cel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, uses CRISPR-Cas9 to edit patients' own stem cells, effectively reactivating foetal haemoglobin production to compensate for the defective adult haemoglobin. Clinical trial data published in early 2026 confirms that 97% of treated patients are "vaso-occlusive crisis free" for at least 24 months post-treatment.
This is remarkable. Patients who previously suffered multiple painful crises per year — often requiring hospitalisation — are now living without symptoms. The NHS began offering the treatment to eligible patients in late 2025, though supply and eligibility criteria remain limited.
"This is the closest thing to a cure that medicine has ever delivered for sickle cell disease. One treatment. Potentially lifelong benefit." — Prof. Stuart Orkin, Harvard Medical School
Breakthrough 2: Gene Therapy for Inherited Blindness
Luxturna, a gene therapy for RPE65-mutation-associated retinal dystrophy, has been available since 2020 — but 2026 data from long-term follow-up studies confirms lasting visual improvements in patients treated seven years ago. More significantly, the approach is being adapted for other forms of inherited blindness.
A new therapy targeting RPGR-associated retinitis pigmentosa (a more common form affecting predominantly men) is currently in Phase 3 trials, with results expected later in 2026. Early data looks highly promising.
Breakthrough 3: In Vivo CRISPR — Treating Inside the Body
Until recently, most gene therapies required removing cells from the body, editing them in a laboratory, and reinfusing them. The next frontier — in vivo gene editing — involves delivering CRISPR tools directly into the bloodstream to edit cells inside the body.
In January 2026, results from Intellia Therapeutics' NTLA-2001 trial confirmed that a single infusion of in vivo CRISPR editing reduced disease-causing protein levels by over 90% in patients with hereditary transthyretin amyloidosis (a serious heart and nerve disease). This approach, if it generalises, could eventually be adapted for a much wider range of conditions.
Breakthrough 4: Cancer-Fighting CAR-T Therapies Expand
CAR-T therapy — which genetically engineers a patient's immune cells to recognise and attack cancer — has been approved for certain leukaemias and lymphomas for several years. In 2026, the scope has expanded significantly:
- Multiple myeloma: Two new CAR-T therapies approved by NICE in England for relapsed cases, offering remission in over 70% of trial participants.
- Solid tumours: Previously, CAR-T largely failed against solid tumours (like lung or breast cancer). New "armoured" CAR-T designs are showing early promise in Phase 1/2 trials.
- Off-the-shelf CAR-T: Allogeneic (donor-derived) CAR-T cells are entering late-stage trials, which could dramatically reduce cost and production time compared to personalised approaches.
Private health insurance can give you faster access to specialists working with the latest therapies. Compare UK health insurance providers and find a plan that fits your needs.
Compare Health Insurance Plans →What Gene Therapy Still Can't Do
It's important to be honest about limitations. Gene therapy is not a universal solution:
- Cost: Approved therapies like Casgevy cost over $2 million per patient in the US. NHS access is available for some, but globally access is severely limited by price.
- Complex diseases: Conditions like Alzheimer's, type 2 diabetes, or most cancers involve hundreds of genes and environmental factors — far beyond the reach of current gene editing approaches.
- Long-term safety: Most therapies are too new for true long-term data. Unintended off-target edits remain a theoretical concern, even if none have been observed in trials so far.
What's Next: The Conditions in the Pipeline
Late-stage clinical trials in 2026 include gene therapies for: haemophilia A and B (several now approved or near-approval), Duchenne muscular dystrophy, certain forms of deafness, high cholesterol (PCSK9 editing), and chronic hepatitis B. The pace of development has accelerated sharply since CRISPR tools became more precise and delivery mechanisms improved.
